Stay updated on PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial
Sign up to get notified when there's something new on the PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial page.

Latest updates to the PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial page
- Check3 days agoChange DetectedA new revision entry is added to the Record History: Revision: v3.3.4. This is a routine site revision update and does not modify trial data or study details.SummaryDifference0.1%

- Check10 days agoChange DetectedRecord History now lists the latest known status and sponsor (Jiangsu HengRui Medicine Co., Ltd.) with a 2022-10 date, and includes Recruitment Status and Study Status details as of 2022-11-16.SummaryDifference0.9%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedA new revision label (Revision: v3.3.3) was added to the History. The HHS Vulnerability Disclosure link and Revision: v3.3.2 were removed from the footer.SummaryDifference0.2%

- Check53 days agoChange DetectedThe Record History now includes a new revision entry v3.3.2 and removes v3.2.0 from the list. This updates the visible revision history and reflects the latest changes to the trial record.SummaryDifference0.1%

- Check60 days agoChange DetectedThe government funding notice/banner at the top of the page has been removed, and the trial record content and navigation remain unchanged; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check74 days agoChange DetectedVersion history shows updates to Study Status and Recruitment Status, including changes to Contacts/Locations. These updates reflect changes in the trial's current activity and site information.SummaryDifference0.1%

Stay in the know with updates to PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial page.